Omicron neutralising antibodies after COVID-19 vaccination in haemodialysis patients

[1]  S. Jaffe.  The next steps for US vaccine mandates , 2022, The Lancet.

[2]  A. Sigal,et al.  SARS-CoV-2 spike T cell responses induced upon vaccination or infection remain robust against Omicron , 2021, medRxiv.

[3]  M. Kraemer,et al.  Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa , 2021, Nature.

[4]  V. Libri,et al.  Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial , 2021, The Lancet.

[5]  L. Smeeth,et al.  Describing the population experiencing COVID-19 vaccine breakthrough following second vaccination in England: a cohort study from OpenSAFELY , 2021, BMC Medicine.

[6]  A. Davenport,et al.  Neutralising antibodies after COVID-19 vaccination in UK haemodialysis patients , 2021, The Lancet.

[7]  P. Kelleher,et al.  Comparison of immunogenicity between BNT162b2 and ChAdOx1 SARS-CoV-2 vaccines in a large haemodialysis population , 2021, medRxiv.

[8]  C. Swanton,et al.  AZD1222-induced neutralising antibody activity against SARS-CoV-2 Delta VOC , 2021, The Lancet.

[9]  C. Swanton,et al.  Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination , 2021, The Lancet.

[10]  J. Hughes,et al.  Genetic epidemiology of SARS-CoV-2 transmission in renal dialysis units – A high risk community-hospital interface , 2021, Journal of Infection.